Department of Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Ann Surg Oncol. 2022 Oct;29(10):6428-6437. doi: 10.1245/s10434-022-12189-6. Epub 2022 Aug 1.
Lymphedema is a potential lifelong sequela of breast cancer treatment. We sought to: (1) evaluate the worry and knowledge of patients about lymphedema, (2) quantify patients reporting lymphedema education and screening, and (3) determine willingness to participate in lymphedema screening and prevention programs.
A survey evaluating lymphedema-related knowledge and worry was sent to patients treated for stage 0-III breast cancer. Exclusion criteria included > 10 years since diagnosis, missing clinical staging, and those without axillary surgery. Responses were linked with clinicopathologic information.
Of 141 patients meeting inclusion criteria, 89% of those without lymphedema were not at all or slightly worried about lymphedema. Higher levels of worry were associated with clinical stage II-III disease [odds ratio (OR) 2.63, p = 0.03], a history of axillary lymph node dissection (ALND) (OR 4.58, p < 0.01), and employment (OR 2.21, p = 0.05). A total of 102 (72%) patients recalled receiving lymphedema education. Lymphedema knowledge was limited, with < 25% of respondents answering > 50% of the risk factor questions correctly. Worry and knowledge were not significantly associated. Of patients without lymphedema, 36% were interested in learning more about lymphedema and 64% were willing to participate in or learn more about a screening program. Most (66%) felt that lymphedema information should be provided before and after cancer treatment.
A majority of our breast cancer survivors had limited knowledge about lymphedema risk factors. While most patients were not worried about developing lymphedema, higher worry was seen in patients with a higher clinical stage at diagnosis, ALND, and employment. Our findings suggest potential targets and timing for patient-centered educational interventions.
淋巴水肿是乳腺癌治疗的潜在终身后遗症。我们试图:(1)评估患者对淋巴水肿的担忧和认识,(2)量化报告淋巴水肿教育和筛查的患者数量,以及(3)确定参与淋巴水肿筛查和预防计划的意愿。
一项评估与淋巴水肿相关的知识和担忧的调查被发送给接受 0-III 期乳腺癌治疗的患者。排除标准包括诊断后 > 10 年、临床分期缺失和无腋窝手术。反应与临床病理信息相关联。
在符合纳入标准的 141 名患者中,89%无淋巴水肿的患者对淋巴水肿一点也不担心或稍有担心。更高水平的担忧与临床分期 II-III 期疾病相关(优势比[OR]2.63,p = 0.03)、腋窝淋巴结清扫术(ALND)史(OR 4.58,p < 0.01)和就业(OR 2.21,p = 0.05)。共有 102 名(72%)患者回忆起接受过淋巴水肿教育。淋巴水肿知识有限,只有不到 25%的受访者答对了超过 50%的危险因素问题。担忧和知识没有显著相关性。在没有淋巴水肿的患者中,36%有兴趣更多地了解淋巴水肿,64%愿意参与或更多地了解筛查计划。大多数(66%)人认为应该在癌症治疗前后提供淋巴水肿信息。
我们的大多数乳腺癌幸存者对淋巴水肿风险因素的了解有限。虽然大多数患者对发生淋巴水肿并不担心,但在诊断时临床分期较高、ALND 和就业的患者中,担忧程度更高。我们的发现表明,针对以患者为中心的教育干预的潜在目标和时机。